Travere Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Travere Therapeutics (San Diego, CA): 2 reconciled FDA prescription therapies, $77.9M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterSan Diego, CA
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2037-01-01
2024 CMS Total Public Spend$77.9M
2024 Medicare Part D Spend$43.7M
2024 Medicaid Spend$34.1M
California HCAI SB 17 Filings8 WAC filings (max 33.7% 2-yr change)